While Lilly and Eisai/Biogen validated the amyloid theory in Alzheimer's disease, there are several trials of drugs with ...

On 24 September, uniQure announced positive topline results from its pivotal Phase I/II studies (HD-GENE-TRX1, HD-GENE-TRX2) ...

PepGen’s stock has risen by over 120% after its investigational myotonic DM1 candidate reported the highest mean splicing ...

Though Eli Lilly has shelved the obesity and T2D trial involving Zepbound, the US pharma will continue its obesity-only trial ...

Pi Health is to deliver outsourced clinical research services in a GSK oncology study to enhance the efficiency and speed of ...

As China's biotech sector continues to buzz with innovation, the country is rapidly integrating into the global clinical ...

Bayer vice president Luiz Barberini explains how the German giant’s cooperation with suppliers fosters long-term trial ...

MediciNova has completed full patient enrolment in the COMBAT-ALS Phase IIb/III clinical trial of MN-166 (ibudilast) as a ...

Datavant has partnered with life sciences commercialisation firm Indegene to enhance recruitment of subjects for clinical ...

AstraZeneca’s Saphnelo (SC) administration has shown a decrease in disease activity in individuals with systemic lupus ...

In a pair of Phase III trials, J&J and Protagonists' icotrokinra beat BMS' Sotyktu on every skin-clearness measure.

Kairos Pharma has reported encouraging interim efficacy data from its Phase II study of ENV105 in individuals with mCRPC.